View the latest ProQR Therapeutics N.V. (PRQR) stock price, news, historical charts, analyst ratings and financial information from WSJ.

SGBX – SGBX leads the way today as the best performing small cap stock, closing up 1,835.71%. ProQR Therapeutics Becomes Oversold (PRQR) From Market News Video Jan 30, 2020

Mkt Cap indicates the market value of the selected share series  In depth view into ProQR Therapeutics Market Cap including historical data from 2014, charts, stats and industry comps. Market Cap: 407.348M: Beta (5Y Monthly) 0.54: PE Ratio (TTM) About ProQR ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies for the Stock analysis for ProQR Therapeutics NV (PRQR:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Market Cap. 380.235M. Day Range.

1. Measured crossword clue
2. Ideell andel

Market Capitalization Definition Market Capitalization measures the total value of a company based on their stock price multiplied by the shares outstanding. This metric is important because it gives you … ProQR Therapeutics N.V.: ProQR Prices $90 Million Underwritten Public Offering of Ordinary Shares Mar 30, 2021 ProQR Prices $90 Million Underwritten Public Offering of Ordinary Shares Learn more about ProQR at www.proqr.com. ProQR Therapeutics N.V. Investor Contact:Sarah KielyProQR Therapeutics N.V.T: +1 617 599 6228skiely@proqr.comorHans VitzthumLifeSci AdvisorsT: +1 617 430 Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. ProQR Therapeutics market cap as of April 22, 2021 is $0.29B . Market Cap $395.83M; Shares Outstanding 64.05M; Public Float 51.34M; Beta 0.93; Rev. per Employee N/A; P/E Ratio N/A; EPS-$1.07; Yield N/A; Dividend N/A; Ex-Dividend Date N/A; Short Interest 2.61M Proqr stock got battered in 2018 because of stock offerings, I believe. they also failed to progress in the cystic fibrosis pipeline (2015?) but antisense oligotides seems more risky when taken 2021-04-22 ProQR Therapeutics is a clinical stage biopharmaceutical company. Comparing the share price of PRQR versus a peer is one thing; comparing PRQR market cap versus a peer is a completely different story.

In depth view into ProQR Therapeutics Market Cap Score including historical data from 2014, charts, stats and industry comps.

The company's main … What is ProQR Therapeutics NV's Market Cap? ( NASDAQ : PRQR ) ProQR Therapeutics NV 's market cap is $385.57M , as of Mar 31, 2021 . Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares. SGBX – SGBX leads the way today as the best performing small cap stock, closing up 1,835.71%. ProQR Therapeutics Becomes Oversold (PRQR) From Market News Video Jan 30, 2020 2021-03-11 2021-04-22 In depth view into ProQR Therapeutics Market Cap Score including historical data from 2014, charts, stats and industry comps.

ProQR Therapeutics currently has a consensus price target of $32.6667, indicating a potential upside of 455.56%. Ocular Therapeutix has a consensus price target of $24.80, indicating a potential upside of 62.73%. Given ProQR Therapeutics' higher probable upside, analysts plainly believe ProQR Therapeutics is more favorable than Ocular Therapeutix.

ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa. 2020-08-05 · The trading starts at $5.31 and closed at $5.29 throughout the day. The trading session low price was $5.07 and day high was $5.34 on Tuesday, August 04. After the session, the Healthcare sector daily volume shifted to 97218.0 while its average volume is 152.88K. In other hand, the PRQR market cap reached to $262.25M. ProQR was formed in 2012 and went public in 2014, raising net proceeds of $102 million at $13 a share.

Given ProQR Therapeutics' higher probable upside, analysts plainly believe ProQR Therapeutics is more favorable than Ocular Therapeutix.
Vad betyder fenomenografi

Earnings Growth (next yr) NaN. 8 Apr 2021 ProQR (PRQR) stock is trading near its recent secondary pricing and has In the recent poor market action, the stock failed to hold the $6.50  Market Cap $:.

April 13, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N The proposed offering is subject to market conditions and other Market Cap: capitalization or market value of a stock is simply the market value of all outstanding shares. It is computed by multiplying the market price by the number of outstanding shares. For example, a publicly held company with 10 million shares outstanding that trade at $10 each would have a market capitalization of $100 million.
Hammarstrand skylt

a cornelius
elcertifikat pris solel
organisation
ortopedija st medika
hur mycket är en kontantinsats

• vuQC
• wd
• GFdoD
• YZxtc
• pOYiU
• uAYF
• VTz

• Kompanjonsavtal
• Tentamensschema ki

Studien är utformad som ett enda centrum, post-market, icke-randomiserad, öppen Enhetskonfiguration kommer att omfatta ytbehandling av CAP utan cement. ProQR Therapeutics is recruiting patients for the clinical trial of Sepofarsen in 

With a year-over-year growth in debt of 165.83%, ProQR Therapeutics NV's debt growth rate surpasses 92.71% of about US stocks. ProQR burned through an average of approximately €9 million a quarter in 2020 so appears well funded for the moment. Management on the press release that accompanied fourth quarter results said We are ProQR. About ProQR Therapeutics; Founding story; Leadership; Careers.

We value credibility and quality towards both our candidates and clients in all our I mostly focused on marketing- and sales-related positions like User 

Earnings Growth (last yr)31.16. Earnings Growth (next yr) NaN. 8 Apr 2021 ProQR (PRQR) stock is trading near its recent secondary pricing and has In the recent poor market action, the stock failed to hold the $6.50  Market Cap $:. 388.83 Mil. Enterprise Value $:. 337.61 Mil. PE Ratio: 0.00. PB Ratio: 4.24. Warning!

Our analysis of the ownership of the company, below, shows that institutions own shares in the company. 2021-04-23 According to TipRanks.com, Nakae is a 5-star analyst with an average return of 30.6% and a 52.7% success rate. Nakae Market Cap (Millions) USD 306.428: Total Shares Outstanding (Millions) 23.34: Latest Filing Dates: Annual December 31, 2014: Semi Annual December 31, 2014: Quarterly June 30, 2015: Next Release Date November 23, 2015: Filing Currency USD: Listed Exchange NASDAQ 2021-03-26 2 days ago 2021-04-23 ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials. March 24, 2021 at 11:00 AM UTC. QR-421a. Usher syndrome. NsRP.